Xilio Taps Former Tesaro Exec Martin Huber as Chief Medical Officer

Xconomy Boston — 

Xilio Therapeutics has appointed Martin Huber to serve as its chief medical officer, the same position he held at Tesaro before its 2018 acquisition by GlaxoSmithKline (NYSE: GSK). His experience also includes roles at Merck (NYSE: MRK), Schering-Plough, Roche, and Rhone-Poulenc Rorer. Waltham, MA-based Xilio is developing antibody cancer drugs designed to activate their cancer-killing activity at the site of the tumor. In March, the biotech raised $100.5 million in Series B financing.